Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-&beta;1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

375

HTML

2139

Figures (1-2)

228

Tables (1-4)

181

Sum=2923

Nov 21, 2005 (publication date) through Nov 3, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 21, 2005; 11(43): 6833-6838
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6833

Table 1 Plasma concentrations of TGF-β1, TIMP-1, and MMP-1 during treatment (mean±SE)

	Controls	Weeks after starting treatment
		0	24	48	72
TGF-β1 (ng/mL)	18.3±1.6	30.9±3.7^a	21.2±2.8^c	17.9±2.0^c	21.0±2.5^c
TIMP-1 (ng/mL)	1 102±67	1 506±61^a	1 372±70^a	1 389±51^a	1410±66^a
MMP-1 (ng/mL)	11.9±0.9	6.5±0.9^a	7.2±1.5^a	7.5±2.6	8.0±1.6

^aP<0.05 vs normal,

^cP<0.05 vs baseline.

Citation: Flisiak R, Jaroszewicz J, Łapiński TW, Flisiak I, Prokopowiczi D. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-β1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol 2005; 11(43): 6833-6838
URL: https://www.wjgnet.com/1007-9327/full/v11/i43/6833.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i43.6833